Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro-Oncology. 2018;20:iv1–iv86. https://doi.org/10.1093/neuonc/noy131.
Article
PubMed
PubMed Central
Google Scholar
Kraywinkel K, Spix C. Epidemiologie primärer Hirntumoren bei Kindern und Erwachsenen in Deutschland. Onkologe. 2019;25:5–9. https://doi.org/10.1007/s00761-018-0501-1.
Article
Google Scholar
Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–10. https://doi.org/10.1093/jnci/85.9.704.
Article
PubMed
Google Scholar
Niyazi M, Adeberg S, Kaul D, Boulesteix AL, Bougatf N, Fleischmann DF, et al. Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: a multicenter DKTK/ROG analysis. Radiother Oncol. 2018;127:121–7. https://doi.org/10.1016/j.radonc.2018.01.011.
Article
PubMed
Google Scholar
Lee J, Park SH, Kim YZ. Prognostic evaluation of neurological assessment of the Neuro-oncology scale in Glioblastoma patients. Brain Tumor Res Treat. 2018;6:22–30. https://doi.org/10.14791/btrt.2018.6.e1.
Article
PubMed
PubMed Central
Google Scholar
Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998;40:51–5. https://doi.org/10.1016/s0360-3016(97)00485-9.
Article
CAS
PubMed
Google Scholar
Siegel EM, Nabors LB, Thompson RC, Olson JJ, Browning JE, Madden MH, et al. Prediagnostic body weight and survival in high grade glioma. J Neuro-Oncol. 2013;114:79–84. https://doi.org/10.1007/s11060-013-1150-2.
Article
Google Scholar
Potharaju M, Mangaleswaran B, Mathavan A, John R, Thamburaj V, Ghosh S, et al. Body mass index as a prognostic marker in Glioblastoma Multiforme: a clinical outcome. Int J Radiat Oncol Biol Phys. 2018;102:204–9. https://doi.org/10.1016/j.ijrobp.2018.05.024.
Article
PubMed
Google Scholar
Jones LW, Ali-Osman F, Lipp E, Marcello JE, McCarthy B, McCoy L, et al. Association between body mass index and mortality in patients with glioblastoma mutliforme. Cancer Causes Control. 2010;21:2195–201. https://doi.org/10.1007/s10552-010-9639-x.
Article
PubMed
PubMed Central
Google Scholar
Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27:1082–6. https://doi.org/10.1200/jco.2008.19.1098.
Article
PubMed
PubMed Central
Google Scholar
Tieu MT, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar BA, et al. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. J Neuro-Oncol. 2015;124:119–26. https://doi.org/10.1007/s11060-015-1815-0.
Article
CAS
Google Scholar
Adeberg S, Bernhardt D, Foerster R, Bostel T, Koerber SA, Mohr A, et al. The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma. Acta Oncol. 2016;55:201–7. https://doi.org/10.3109/0284186x.2015.1043397.
Article
PubMed
Google Scholar
Klement RJ, Champ CE. Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. Brain. 2017;140:e16. https://doi.org/10.1093/brain/aww324.
Article
PubMed
Google Scholar
Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24:2563–9. https://doi.org/10.1200/jco.2005.04.5963.
Article
CAS
PubMed
Google Scholar
Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–9. https://doi.org/10.1200/jco.2005.03.4157.
Article
PubMed
Google Scholar
Quick J, Gessler F, Dutzmann S, Hattingen E, Harter PN, Weise LM, et al. Benefit of tumor resection for recurrent glioblastoma. J Neuro-Oncol. 2014;117:365–72. https://doi.org/10.1007/s11060-014-1397-2.
Article
CAS
Google Scholar
Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306–16. https://doi.org/10.1001/jama.2017.18718.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. https://doi.org/10.1056/NEJMoa043330.
Article
CAS
PubMed
Google Scholar
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003. https://doi.org/10.1056/NEJMoa043331.
Article
CAS
PubMed
Google Scholar
Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology. 2014;16:81–91. https://doi.org/10.1093/neuonc/not159.
Article
CAS
PubMed
Google Scholar
Wee CW, Kim E, Kim N, Kim IA, Kim TM, Kim YJ, et al. Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: a multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. Radiother Oncol. 2017;123:106–11. https://doi.org/10.1016/j.radonc.2017.02.014.
Article
CAS
PubMed
Google Scholar
Wee CW, Kim IH, Park C-K, Kim JW, Dho Y-S, Ohka F, et al. Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: a multi-institutional collaborative study. Radiother Oncol. 2018;129:347–51. https://doi.org/10.1016/j.radonc.2018.09.001.
Article
PubMed
Google Scholar
Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5:1725–31. https://doi.org/10.1016/0360-3016(79)90553-4.
Article
CAS
PubMed
Google Scholar
Thames HD Jr, Peters LJ, Withers HR, Fletcher GH. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys. 1983;9:127–38. https://doi.org/10.1016/0360-3016(83)90089-5.
Article
PubMed
Google Scholar
Withers HR. Biologic basis for altered fractionation schemes. Cancer. 1985;55:2086–95. https://doi.org/10.1002/1097-0142(19850501)55:9+<2086::aid-cncr2820551409>3.0.co;2-1.
Article
CAS
PubMed
Google Scholar
Roberts SA, Hendry JH. A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity. Int J Radiat Oncol Biol Phys. 1998;41:689–99. https://doi.org/10.1016/s0360-3016(98)00100-x.
Article
CAS
PubMed
Google Scholar
Joiner M. Kogel Avd. Basic clinical radiobiology. Fifth edition. Ed. Boca Raton: CRC Press/Taylor & Francis Group; 2018.
Book
Google Scholar
Curran WJ Jr, Scott CB, Nelson JS, Weinstein AS, Phillips TL, Murray K, et al. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of radiation therapy oncology group 83-02. Cancer. 1992;70:2909–17.
Article
Google Scholar
Werner-Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach JA, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation therapy oncology group study 83-02. Cancer. 1996;77:1535–43. https://doi.org/10.1002/(sici)1097-0142(19960415)77:8<1535::aid-cncr17>3.0.co;2-0.
Article
CAS
PubMed
Google Scholar
Lutterbach J, Weigel P, Guttenberger R, Hinkelbein W. Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme. Radiother Oncol. 1999;53:49–52.
Article
CAS
Google Scholar
Nieder C, Nestle U, Ketter R, Kolles H, Gentner SJ, Steudel WI, et al. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme. Radiat Oncol Investig. 1999;7:36–41. https://doi.org/10.1002/(sici)1520-6823(1999)7:1<36::aid-roi5>3.0.co;2-o.
Article
CAS
PubMed
Google Scholar
Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;49:71–7.
Article
CAS
Google Scholar
Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, et al. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neuro-Oncol. 2018;137:39–47. https://doi.org/10.1007/s11060-017-2558-x.
Article
Google Scholar
Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-course radiation plus Temozolomide in elderly patients with Glioblastoma. N Engl J Med. 2017;376:1027–37. https://doi.org/10.1056/NEJMoa1611977.
Article
CAS
PubMed
Google Scholar
Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916–26. https://doi.org/10.1016/S1470-2045(12)70265-6.
Article
CAS
PubMed
Google Scholar
Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583–8. https://doi.org/10.1200/JCO.2004.06.082.
Article
CAS
PubMed
Google Scholar
Navarria P, Pessina F, Tomatis S, Soffietti R, Grimaldi M, Lopci E, et al. Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. Oncotarget. 2017;8:67696–708. https://doi.org/10.18632/oncotarget.18809.
Article
PubMed
PubMed Central
Google Scholar
Guckenberger M, Mayer M, Buttmann M, Vince GH, Sweeney RA, Flentje M. Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. Strahlenther Onkol. 2011;187:548–54. https://doi.org/10.1007/s00066-011-2242-6.
Article
PubMed
Google Scholar
Kaul D, Florange J, Badakhshi H, Grun A, Ghadjar P, Exner S, et al. Accelerated hyperfractionation plus temozolomide in glioblastoma. Radiat Oncol. 2016;11:70. https://doi.org/10.1186/s13014-016-0645-3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers EJ, Berk R, et al. Redefine statistical significance. Nat Hum Behav. 2018;2:6–10. https://doi.org/10.1038/s41562-017-0189-z.
Article
PubMed
Google Scholar
Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Bmj. 2009;338:b2393. https://doi.org/10.1136/bmj.b2393.
Article
PubMed
PubMed Central
Google Scholar
van Buuren S, Groothuis-Oudshoorn K. Mice: Multivariate Imputation by Chained Equations in R. 2011;45:67. https://doi.org/10.18637/jss.v045.i03.
Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology RTOG 0525 and 0825. Neuro-Oncology. 2017;19:669–77. https://doi.org/10.1093/neuonc/now208.
Article
PubMed
Google Scholar
Lee AW, Foo W, Chappell R, Fowler JF, Sze WM, Poon YF, et al. Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1998;40:35–42. https://doi.org/10.1016/s0360-3016(97)00580-4.
Article
CAS
PubMed
Google Scholar
Lambrecht M, Eekers DBP, Alapetite C, Burnet NG, Calugaru V, Coremans IEM, et al. Radiation dose constraints for organs at risk in neuro-oncology; the European particle therapy network consensus. Radiother Oncol. 2018. https://doi.org/10.1016/j.radonc.2018.05.001.
McDonald MW, Linton OR, Calley CSJ. Dose-Volume Relationships Associated With Temporal Lobe Radiation Necrosis After Skull Base Proton Beam Therapy. Int J Radiat Oncol Biol Phys. 2015;91:261–7. https://doi.org/10.1016/j.ijrobp.2014.10.011.
Article
PubMed
Google Scholar
Pedicini P, Fiorentino A, Simeon V, Tini P, Chiumento C, Pirtoli L, et al. Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes. Strahlenther Onkol. 2014;190:925–32. https://doi.org/10.1007/s00066-014-0638-9.
Article
PubMed
Google Scholar
Haviland JS, Bentzen SM, Bliss JM, Yarnold JR. Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: an analysis of the UK START (standardisation of breast radiotherapy) trials of radiotherapy fractionation. Radiother Oncol. 2016;121:420–3. https://doi.org/10.1016/j.radonc.2016.08.027.
Article
PubMed
Google Scholar
Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer. 2005;5:55. https://doi.org/10.1186/1471-2407-5-55.
Article
PubMed
PubMed Central
Google Scholar
Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, et al. Multicenter, phase 1, dose escalation study of Hypofractionated stereotactic radiation therapy with Bevacizumab for recurrent Glioblastoma and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 2017;99:797–804. https://doi.org/10.1016/j.ijrobp.2017.06.2466.
Article
CAS
PubMed
PubMed Central
Google Scholar
Levy S, Chapet S, Scher N, Debbi K, Ruffier A, Bernadou G, et al. Reirradiation of gliomas under stereotactic conditions: prognostic factors for survival without relapse or side effects, a retrospective study at Tours regional university hospital (France). Cancer Radiother. 2017;21:759–65. https://doi.org/10.1016/j.canrad.2017.05.006.
Article
CAS
PubMed
Google Scholar
Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, et al. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Radiat Oncol. 2015;10:222. https://doi.org/10.1186/s13014-015-0527-0.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wong ET, Lok E, Gautam S, Swanson KD. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer. 2015;113:232–41. https://doi.org/10.1038/bjc.2015.238.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016;139:1458–71. https://doi.org/10.1093/brain/aww046.
Article
PubMed
PubMed Central
Google Scholar